AMD drug approval sparks controversy

A drug hailed by opthamologists as the first treatment to effectively treat the wet form of age-related macular degeneration (AMD), is at the center of an international clash between doctors and the pharmaceutical industry.

Add a Comment

Your display name This field is mandatory

Your e-mail address This field is mandatory (Your e-mail address won't be published)

Security code